PRD-XL

PRD-XL is an experimental recombinant fusion protein construct designed for cancer therapy by targeting the mitochondrial apoptotic pathway. It consists of the proline-rich domain (PRD) of the tumor suppressor protein p53 fused to the mitochondrial targeting signal (MTS) derived from the anti-apoptotic protein Bcl-XL. The construct is engineered to localize specifically to the mitochondria, where the p53 PRD domain interacts with and inhibits Bcl-XL. This inhibition facilitates the release and activation of pro-apoptotic proteins such as Bak and Bax, leading to mitochondrial outer membrane permeabilization and the induction of apoptosis. Developed by researchers at the University of Utah, PRD-XL has been evaluated in preclinical studies across various cancer cell lines, including breast cancer, cervical cancer, and leukemia models, to investigate the efficacy of specific p53 subdomains in triggering mitochondrial-mediated cell death.

Other names

p53 proline-rich domain fused to Bcl-XL mitochondrial targeting signalp-53 proline-rich domain fused to Bcl-XL mitochondrial targeting signalp 53 proline-rich domain fused to Bcl-XL mitochondrial targeting signal